Susquehanna International Group
TRVI icon

Susquehanna International Group’s Trevi Therapeutics TRVI Stock Holding History

Susquehanna International Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77M Buy
148,500
+73,400
+98% +$822K ﹤0.01% 6449
2025
Q4 		$940K Sell
75,100
-337,600
-82% -$3.9M ﹤0.01% 7330
2025
Q3 		$3.78M Sell
412,700
-44,600
-10% -$334K ﹤0.01% 4570
2025
Q2 		$2.5M Buy
457,300
+302,500
+195% +$1.88M ﹤0.01% 5331
2025
Q1 		$974K Buy
154,800
+133,000
+610% +$634K ﹤0.01% 7326
2024
Q4 		$89.8K Buy
21,800
+10,100
+86% +$32.3K ﹤0.01% 11412
2024
Q3 		$39.1K Sell
11,700
-3,900
-25% -$11.6K ﹤0.01% 11467
2024
Q2 		$46.5K Buy
+15,600
New +$43.3K ﹤0.01% 11441
2023
Q3 		– Sell
-18,700
Closed -$44.7K – 13006
2023
Q2 		$44.7K Buy
+18,700
New +$47.1K ﹤0.01% 11380

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Susquehanna International Group's TRVI Position: Q1 2026 in Review

Susquehanna International Group reduced its Trevi Therapeutics (TRVI) stake by 72% in Q1 2026, selling an estimated $6.69M and leaving 227,688 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #5483.

Susquehanna International Group first reported a position in TRVI in Q4 2020 and has held it in 11 quarters since. The position peaked at $14.6M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Susquehanna International Group held 227,688 shares of Trevi Therapeutics worth $2.72M as of Q1 2026.
  • Susquehanna International Group sold 597,860 Trevi Therapeutics shares in Q1 2026, an estimated $6.69M.
  • Trevi Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5483 holding.
  • Susquehanna International Group first reported a position in Trevi Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Susquehanna International Group's Trevi Therapeutics position peaked at $14.6M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.